Impact of time of onset of symptom of ST-segment elevation myocardial infarction on 1-year rehospitalization for heart failure and mortality.


Journal

American heart journal
ISSN: 1097-6744
Titre abrégé: Am Heart J
Pays: United States
ID NLM: 0370465

Informations de publication

Date de publication:
06 2020
Historique:
received: 01 12 2019
accepted: 16 03 2020
pubmed: 8 4 2020
medline: 17 7 2020
entrez: 8 4 2020
Statut: ppublish

Résumé

Circadian patterns in ST-segment elevation myocardial infarction (STEMI) patients have been previously reported, but little is known about the impact of time dependence of symptom onset on long-term prognosis. Our study population consisted of 11,731 STEMI patients treated by primary percutaneous coronary intervention (PPCI), enrolled in the Singapore Myocardial Infarction Registry (SMIR). Analysis of STEMI incidence trends over the 24-hour period showed the highest rate of symptom onset in the morning, with the peak incidence at 09:00 am. Patients with symptom onset in between 00:00 am-5:59 am showed the highest prevalence of diabetes (P = .010) and anterior STEMI (P < .001) and had the longest ischemic time (P < .001). After adjusting for confounders, we found an association between time of symptom onset of STEMI and rehospitalization for heart failure (HF) at 1 year, with symptom onset between 06:00 pm-11:59 pm and 00:00 am-05:59 am having an estimated 30% to 50% higher risk of rehospitalization for HF at 1 year. Moreover, symptom onset remained a predictor of worse prognosis only in the subgroup of patients with symptoms lasting longer than 120 minutes. The results of this study demonstrate for the first time that rehospitalization for HF in STEMI patients treated with PPCI has a dependence on the time of onset of symptoms, with prolonged ischemia time playing a pivotal role. This may be an additional risk factor to identify those who warrant closer monitoring and more rigorous optimization of their treatment at follow-up, to improve their outcomes.

Identifiants

pubmed: 32259591
pii: S0002-8703(20)30087-9
doi: 10.1016/j.ahj.2020.03.011
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-9

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Valeria Paradies (V)

National Heart Centre Singapore, Singapore, Singapore.

Huili Zheng (H)

National Registry of Disease Office, Health Promotion Board, Singapore.

Mervyn H H Chan (MHH)

National Heart Centre Singapore, Singapore, Singapore; Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore, Singapore, Singapore.

Mark Yan Yee Chan (MYY)

National University Heart Centre, Singapore.

David C Foo (DC)

Tan Tock Seng Hospital, Singapore, Singapore.

Chee W Lee (CW)

Khoo Teck Puat Hospital, Singapore, Singapore.

Soo Tek Lim (ST)

National Heart Centre Singapore, Singapore, Singapore.

Huay C Tan (HC)

National University Heart Centre, Singapore.

Jack Wei Chieh Tan (JWC)

National Heart Centre Singapore, Singapore, Singapore.

Khim L Tong (KL)

Changi General Hospital, Singapore.

Aaron S Wong (AS)

National Heart Centre Singapore, Singapore, Singapore.

Philip E Wong (PE)

National Heart Centre Singapore, Singapore, Singapore.

Khung Keong Yeo (KK)

National Heart Centre Singapore, Singapore, Singapore.

Ling L Foo (LL)

National Registry of Disease Office, Health Promotion Board, Singapore.

Terrance S Chua (TS)

National Heart Centre Singapore, Singapore, Singapore.

Tian H Koh (TH)

National Heart Centre Singapore, Singapore, Singapore.

Heerajnarain Bulluck (H)

National Heart Centre Singapore, Singapore, Singapore; Norfolk and Norwich University Hospital, Norwich, UK; The Hatter Cardiovascular Institute, University College London, London, UK.

Derek J Hausenloy (DJ)

National Heart Centre Singapore, Singapore, Singapore; Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore, Singapore, Singapore; The Hatter Cardiovascular Institute, University College London, London, UK; Cardiovascular Research Center, College of Medical and Health Sciences, Asia University, Taiwan; Yong Loo Lin School of Medicine, National University Singapore, Singapore, Singapore; Tecnologico de Monterrey, Centro de Biotecnologia-FEMSA, Nuevo Leon, Mexico. Electronic address: derek.hausenloy@duke-nus.edu.sg.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH